Chief Executive Officer and Co-Founder, BioVersys AG
Appears in 1 story
Leading BV100 through Phase 3 development
No genuinely new class of antibiotic has reached patients since 1987, and in the nearly four decades since, bacteria have steadily evolved resistance to existing drugs. Carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—is at the top of the WHO's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received FDA clearance to enroll American patients in a Phase 3 pivotal trial of BV100, which reduced 28-day mortality by half in earlier testing.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
